A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results.
Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.
An outpatient multiple myeloma clinic benefited substantially from employing a clinical pharmacist.
In a new consensus paper, experts emphasized that high doses of vitamin D supplementation have no current benefit in the prevention or treatment of COVID-19.
Officials with the FDA have granted priority review for mepolizumab (Nucala, GlaxoSmithKline) in the treatment of patients with hypereosinophilic syndrome.
Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.
New data showed that treatment with hydroxychloroquine was associated with increased mortality in hospitalized patients with COVID-19.
Officials with the FDA have approved Octapharma’s investigational new drug (IND) application for intravenous immune globulin (IVIG) (Human, Octagam 10%) therapy.
AstraZeneca has received funds exceeding $1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford’s coronavirus disease 2019 (COVID-19) vaccine candidate.
Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).